A study on ESKAPE pathogens the BAD Bug with No Drug

  • Dr. K. Dinesh Assistant Professor, Specialist Microbiology, Sree Balaji Medical College and Hospital, Shri Sathya Sai Medical College and Research Hospital.
  • Dr. Mowna Karthick Assistant Professor, Specialist Microbiology, Sree Balaji Medical College and Hospital, Shri Sathya Sai Medical College and Research Hospital.
DOI: https://doi.org/10.17511/jooo.2017.i02.01
Keywords: ESKAPE pathogens, Multi drug resistance, infections, Antibiotics

Abstract

ESKAPE pathogens include Enterococcus faecium, Staphylococcus aureus, Klebsiella pnuemonia, Acieneto bacter baumanii, Pseudomonas aeruginosa and Enterobacter species. Currently all these organisms are the main cause of hospital infections globally and they have the property to effectively escape the effect of antibacterial drugs. UNSTOPPABLE SUCCESS of these SUPERBUGS will lead to UNWINNABLE WAR. The success of these pathogens is mainly because of the mutations, modifications of LPS. As the crisis for the antibiotic resistance continues to grow, the latest IDSA (INFECTIOUS DISEASE SOCIETY OF AMERICA) “Bad Bugs, No Drugs”reports the urge for new antibiotics in the research and development pipeline and proposes steps to tackle the shortage. The aim of the study was to characterize the antimicrobial resistance in ESKAPE pathogens isolated from 330 culture positive clinical sample. Antibiotic resistance was determined by VITEK 2 and manual method was done on Kirby baurermethod. MIC was determined by VITEK 2 and E-Test according to CLSI guidelines. Out of the total cases 63 percent of the culture has ESKAPE pathogens. Except for S.aureus multidrug resistance index of ESKAPE pathogens revealed on increasing trend.in conclusion, ESKAPE pathogens are commonly identified in alarming frequency and knowledge of antimicrobial resistance will be aided for empirical treatment.

Downloads

Download data is not yet available.

References

1. Giske CG, Monnet DL, Cars O, Carmeli Y; ReActAction on Antibiotic Resistance.Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother. 2008 Mar; 52 (3): 813-21. Epub 2007 Dec 10.

2. Rice LB. Federal funding for the study of antimicrobialresistance in nosocomial- pathogens: no ESKAPE.J Infect Dis. 2008 Apr 15;197(8):1079-81. doi: 10. 1086/ 533452.

3. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, Bartlett JG, Edwards J Jr; Infectious Diseases Society of America. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis. 2008 Jan 15;46(2): 155-64. doi: 10.1086/524891.

4. National Nosocomial Infections Surveillance System Report, data summary from January 1992 through June (2004) issued October 2004. Am J Infect Control 2004; 32:470-85.

5. Lim CJ, Cheng AC, Kennon J, Spelman D, Hale D, Melican G, Sidjabat HE, Paterson DL, Kong DC, Peleg AY. Prevalence of multidrug-resistant organisms and risk factors for carriage in long-term care facilities: a nested case-control study. J Antimicrob Chemother. 2014 Jul;69(7):1972-80. doi: 10.1093/jac/dku077. Epub 2014 Apr 7.

6. Federico Perez, Andrea M. Hujer, Kristine M. Hujer, Brooke K. Decker, Philip N. Rather, and Robert A. Bonomo. Global Challenge of Multidrug-Resistant Acinetobacterbaumannii ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. (2007), p. 3471–3484 Vol. 51, No. 10 0066-4804/07/$08.000 doi:10. 1128 /AAC. 01464-06 Copyright © 2007, American Society for Microbiology.

7. Anima Poudyal, Benjamin P. Howden In vitro pharmacodynamics of colistin against multidrugresistant Klebsiella pneumonia new Journal of Antimicrobial Chemotherapy (2008) 62, 1311–1318 doi: 10. 1093/jac/dkn425 Advance Access publication 15 October (2008)

8. Magill S. S., Edwards J. R., Bamberg W., et al. Multistate point-prevalence survey of health careassociated infections. The New England Journal of Medicine. 2014; 370 (13):1198–1208. doi: 10.1056/ nejmoa1306801. [PMC free article] [PubMed] [Cross Ref]

9. Klevens R. M., Edwards J. R., Richards C. L., Jr., et al. Estimating health care-associated infections and deaths in U.S. Hospitals, 2002. Public Health Reports. 2007; 122(2):160–166. [PMC free article] [PubMed]

10. Giedraitienė A, Vitkauskienė A, Naginienė R, Pavilonis A. Antibiotic resistance mechanisms of clinically important bacteria. Medicina (Kaunas). 2011; 47(3):137-46.

11. Wright G. D. Bacterial resistance to antibiotics: enzymatic degradation and modification. Advanced Drug Delivery Reviews. 2005;57(10):1451–1470. doi: 10.1016/j.addr.2005.04.002. [PubMed] [Cross Ref]

12. Wilson DN. Ribosome-targeting antibiotics and mechanisms of bacterialresistance. Nat Rev Microbiol. 2014 Jan;12(1):35-48. doi: 10.1038/nrmicro3155.
CITATION
DOI: 10.17511/jooo.2017.i02.01
Published: 2017-12-31
How to Cite
Dinesh, K., & Karthick, M. (2017). A study on ESKAPE pathogens the BAD Bug with No Drug. Tropical Journal of Ophthalmology and Otolaryngology, 2(2), 19-22. https://doi.org/10.17511/jooo.2017.i02.01
Issue
Vol 2 No 2 (2017): Jul-Dec
Section
Original Article

Copyright (c) 2017 Author (s). Published by Siddharth Health Research and Social Welfare Society

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.